ATOSSA THERAPEUTICS, INC.

(ATOS)
  Report
Delayed Nasdaq  -  05/23 04:00:01 pm EDT
0.9133 USD   -4.81%
05/18Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference
AQ
05/16ATOSSA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/09Earnings Flash (ATOS) ATOSSA THERAPEUTICS Reports Q1 Loss $-0.04
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Atossa Therapeutics to Start Enrolling Participants in AT-H201 Nebulized Formulation Study in COVID Patients

01/18/2022 | 12:49pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ATOS SE 0.97% 25.1 Real-time Quote.-33.51%
ATOSSA THERAPEUTICS, INC. -4.81% 0.9133 Delayed Quote.-40.04%
All news about ATOSSA THERAPEUTICS, INC.
05/18Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conferen..
AQ
05/16ATOSSA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/09Earnings Flash (ATOS) ATOSSA THERAPEUTICS Reports Q1 Loss $-0.04
MT
05/09ATOSSA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
05/09Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corpora..
AQ
05/09Atossa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
04/28Atossa Therapeutics to Present at the Q2 Investor Summit Conference
AQ
04/27Atossa Therapeutics to Present at the Q2 Investor Summit Conference
AQ
04/20Atossa Therapeutics Completes Enrollment in Second Part of Phase 1/2a Trial of COVID-19..
MT
04/20Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201
AQ
More news
Analyst Recommendations on ATOSSA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -28,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,15x
Yield 2022 -
Capitalization 116 M 116 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 7
Free-Float 100,0%
Chart ATOSSA THERAPEUTICS, INC.
Duration : Period :
Atossa Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATOSSA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,91 $
Average target price 6,00 $
Spread / Average Target 557%
EPS Revisions
Managers and Directors
Steven C. Quay Chairman, President & Chief Executive Officer
Kyle Guse CFO, Secretary & Chief Accounting Officer
Devon Payne Director-Clinical Operations
Bernadine Heather Fraser VP-Clinical, Regulatory & CMC Division
Delly Behen Vice President-Administration & Human Resource
Sector and Competitors
1st jan.Capi. (M$)
ATOSSA THERAPEUTICS, INC.-40.04%121
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567